Loading...

ADTX ADITXT INC US FDA Inspections 8-K Filing

DTXT

DTX

ADITXT INC

(ADTX)

2025 8-K

Show Summary

Summary

Investor Meetings

Investor Meetings

Debt-Equity Swaps

Debt-Equity Swaps

Investor Meetings

Debt-Equity Swaps

Investor Meetings

Merger of Equals

Termination of Agreement

Debt-Equity Swaps

Investor Meetings

Debt-Equity Swaps

Clinical Study Update

Stockholder Meeting

Call Option Agreement

Compliance Update

Investment Agreement

Nasdaq Compliance

Corporate Update

Corporate Update

Patent Acquisition

Acquisition Agreement

Merger Agreement

Merger Amendment

Corporate Update

Stockholder Meeting

Stockholder Meeting

IPO Exploration

Therapeutic Progress

Merger Announcement

Acquisition Agreement

Merger Agreement Update

Stakeholder Update

Stock Purchase Agreement

Board Appointment

Stakeholder Update

Nasdaq Compliance Issue

Merger Amendment

Capital Changes

Investor Presentation

Merger Agreement

Securities Agreement

Acquisition Update

Merger Agreement

Securities Purchase Agreement

Amendment to Certificate of...

Securities Purchase Agreement

Merger Agreement

Acquisition Agreement

Acquisition Agreement

Merger Agreement

Securities Purchase Agreeme...

Acquisition Agreement

Amendment to Merger Agreement

Default on Promissory Note

Senior Note Issuance

Notice of Violation of Leas...

Private Placement

Stock Purchase Agreement

Amendment to Merger Agreement

Termination of Merger Agree...

Acquisition Agreement

Default Notice from Landlord

Merger Agreement and Assign...

Loan Disbursement

Merger Agreement and Note I...

Amendment to Merger Filing

Engagement Letter with Daws...

Default on secured notes an...

Acquisition of Senior Indeb...

Merger Agreement

Asset Acquisitions

Equity Issuance

Acquisition of Assets and M...

Acquisition of Evofem Biosc...

Private Placement

Agreements, Compliance, Mer...

Merger Agreement and Exchan...

Consulting Agreement

Asset Purchase Agreement

Merger Agreement

Loan Agreement and Director...

Agreement for Purchase and ...

Delisting Notice and Execut...

Presentation Materials

Departure of Certain Officers

Reverse Stock Split

Annual Meeting of Stockholders

Securities Purchase Agreement

Resignation of Officer

Acquisition Announcement

Agreement for Purchase and ...

Delisting Notice

Asset Purchase Agreement

Securities Purchase Agreement

Consulting Agreement

Regulation FD Disclosure

Agreement for Purchase and ...

Special Meeting Reconvened

Special Meeting Adjourned

External Links:

On April 18, 2025, Aditxt, Inc. provided a weekly update discussing its subsidiary Pearsanta's recent approval to start clinical studies for a blood test for endometriosis. The update was presented by CEO Amro Albanna and Director of Clinical Trials Steve Varvel.

AI Assistant

ADITXT INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.